Sa1729 PATIENT FACTORS ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) TREATMENT CHANGES
Luisa Scott, Alan Fossa, Kyle D. Staller, Lavanya Viswanathan et autres
0 citations
Gastrointestinal Endoscopy
Luisa Scott
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
7Publications signalées
0Citations signalées
0Affiliations récentes
Les domaines associés
Gastrointestinal motility and disordersParathyroid Disorders and TreatmentsGastroesophageal reflux and treatmentsFibromyalgia and Chronic Fatigue Syndrome ResearchDialysis and Renal Disease Management
Les publications récentes
Sa1729 PATIENT FACTORS ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) TREATMENT CHANGES
Luisa Scott, Alan Fossa, Kyle D. Staller, Lavanya Viswanathan et autres
0 citations
Gastroenterology
Treatment Satisfaction with Tenapanor: Real-World Survey of Patients with End-Stage Renal Disease and Hyperphosphatemia
Jessica Kendrick, Luisa Scott, Belinda Gist, Laura Williams
Purpose: Tenapanor (XPHOZAH), approved by the US FDA in October 2023, is indicated to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to or are intolerant of any dose …
us (code pays fourni par la source)
0 citations
Patient Preference and Adherence
Real-World Effectiveness of Tenapanor (XPHOZAH) for Treatment of Hyperphosphatemia in Patients on Dialysis in the United States
Alan J. Fossa, Dhajanae Sylvertooth, Angelo Karaboyas, Brian A. Bieber et autres
Background: Tenapanor (TEN [XPHOZAH]) is approved to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients (pts) who have an inadequate response to phosphate binders (PBs) or who are intolerant of any dose of PBs. …
us (code pays fourni par la source)
0 citations
Journal of the American Society of Nephrology
Treatment Satisfaction with Tenapanor (XPHOZAH): Real-World Survey of Patients with ESRD and Hyperphosphatemia
Jessica Kendrick, Luisa Scott, Belinda Gist, Laura A. Williams
Background: Tenapanor (TEN [XPHOZAH]), approved by the US FDA in October 2023, is indicated to reduce serum phosphorus (P) in adults with chronic kidney disease on dialysis as add-on therapy in patients (pts) who have an inadequate response to or are intolerant …
us (code pays fourni par la source)
0 citations
Journal of the American Society of Nephrology
S1095 Reduction in Gastrointestinal Visits and Portal Messaging Following Tenapanor (IBSRELA) Initiation for Community Gastrointestinal Patients
Alan J. Fossa, Luisa Scott, Asma Khapra, Lavanya Viswanathan et autres
Introduction: Irritable bowel syndrome with constipation (IBS-C) is a chronic disorder of gut-brain interaction (DGBI) associated with high healthcare resource utilization (HCRU). Tenapanor (TEN [IBSRELA]) is a first-in-class, minimally absorbed inhibitor of intestinal sodium/hydrogen exchanger isoform 3 approved for the treatment of …
0 citations
The American Journal of Gastroenterology
Mo1257: PATIENT-REPORTED IBS-C SYMPTOM SEVERITY CORRELATES POSITIVELY WITH FINANCIAL BURDEN: RESULTS FROM THE IBS IN AMERICA 2024 REAL-WORLD SURVEY
Eric D. Shah, Luisa Scott, Johannah Ruddy, Elizabeth R. Stremke et autres
0 citations
Gastroenterology
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.